Merck Serono

Expert Speaker Lineup Revealed for Award Winning RBQM Event

Retrieved on: 
星期二, 八月 1, 2023
Linda, Operation, Associate Director of National Intelligence and Chief Information Officer, Senior, CD, Astellas Pharma, Data management, Tufts Center for the Study of Drug Development, ZS Associates, Vertex, Clinical trial, Quality management, Evolution, Clinical quality management system, Bristol Myers Squibb, Software, Research, ICH, Central Monitoring System, Parexel, AstraZeneca, Marketing, Guidance, Bayer, Alphabet song, Fellow, Drug development, Entrepreneurship, Merck Serono, ZS, Pharmaceutical industry, Management, Fast food, Tutoring, Light

KING OF PRUSSIA, Pa., Aug. 1, 2023 /PRNewswire/ -- CluePoints, the premier provider of Risk-Based Quality Management (RBQM) Software for clinical trials, has revealed the full agenda and speaker lineup for RBQMLive 2023.

Key Points: 
  • Full agenda and keynote speakers announced for industry-leading risk-based quality management event focusing on the global transformation and evolution of RBQM, sponsored by CluePoints.
  • KING OF PRUSSIA, Pa., Aug. 1, 2023 /PRNewswire/ -- CluePoints , the premier provider of Risk-Based Quality Management (RBQM) Software for clinical trials, has revealed the full agenda and speaker lineup for RBQMLive 2023.
  • RBQMLive 2023 is a free, virtual event for anyone working with, interested in, or planning to adopt risk-based approaches to clinical trial management and oversight.
  • We urge everyone to register for the free sessions and gain insight from our fantastic line-up of expert speakers, all leaders in their respective fields."

Expert Speaker Lineup Revealed for Award Winning RBQM Event

Retrieved on: 
星期二, 八月 1, 2023
Linda, Operation, Associate Director of National Intelligence and Chief Information Officer, Senior, CD, Astellas Pharma, Data management, Tufts Center for the Study of Drug Development, ZS Associates, Vertex, Clinical trial, Quality management, Evolution, Clinical quality management system, Bristol Myers Squibb, Software, Research, ICH, Central Monitoring System, Parexel, AstraZeneca, Marketing, Guidance, Bayer, Alphabet song, Fellow, Drug development, Entrepreneurship, Merck Serono, ZS, Pharmaceutical industry, Management, Fast food, Tutoring, Light

KING OF PRUSSIA, Pa., Aug. 1, 2023 /PRNewswire/ -- CluePoints, the premier provider of Risk-Based Quality Management (RBQM) Software for clinical trials, has revealed the full agenda and speaker lineup for RBQMLive 2023.

Key Points: 
  • Full agenda and keynote speakers announced for industry-leading risk-based quality management event focusing on the global transformation and evolution of RBQM, sponsored by CluePoints.
  • KING OF PRUSSIA, Pa., Aug. 1, 2023 /PRNewswire/ -- CluePoints , the premier provider of Risk-Based Quality Management (RBQM) Software for clinical trials, has revealed the full agenda and speaker lineup for RBQMLive 2023.
  • RBQMLive 2023 is a free, virtual event for anyone working with, interested in, or planning to adopt risk-based approaches to clinical trial management and oversight.
  • We urge everyone to register for the free sessions and gain insight from our fantastic line-up of expert speakers, all leaders in their respective fields."

EnteroBiotix appoints Elmar Schnee as Executive Chairman

Retrieved on: 
星期一, 七月 17, 2023
Therapy, Merck Serono, Merck Group, EBX, RTÉ Executive Board, Acquisition, Patient, Growth, Merck, Cirrhosis, Health, Pharmaceutical industry, Management, Serono

GLASGOW, Scotland, July 17, 2023 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, today announced the appointment to its Board of Elmar Schnee as Executive Chairman.

Key Points: 
  • GLASGOW, Scotland, July 17, 2023 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, today announced the appointment to its Board of Elmar Schnee as Executive Chairman.
  • Mr. Schnee brings broad experience from the international pharmaceutical industry and will play a pivotal role in leading EnteroBiotix to deliver on its next phase of growth.
  • As Executive Chairman, Mr. Schnee will work closely with the management team to drive corporate strategy, foster key partnerships, and further strengthen EnteroBiotix's position as a global leader in the microbiome field.
  • We look forward to continuing to work with Douglas and are thrilled to welcome Elmar to EnteroBiotix as Executive Chairman," said Dr James McIlroy, Founder and CEO of EnteroBiotix.

U.S. Businesses of Merck KGaA, Darmstadt, Germany, Named a 'Best Place to Work for Disability Inclusion'

Retrieved on: 
星期二, 七月 11, 2023
Non-U.S. operators of the M60 Patton, Retention, Cross-cultural leadership, Sigma-Aldrich, ERG, Supplier diversity, Minister of Employment, Workforce Development and Disability Inclusion, Benefit, Workplace, Electronics, Merck Group, Equity, Science, Thought, Employment, Employment practices liability, DEI, Merck, Community engagement, Employee resource group, Merck Serono, Environment, Erg, Education, Pharmaceutical industry

The businesses of Merck KGaA, Darmstadt, Germany, operate in the U.S and Canada as MilliporeSigma, EMD Serono, and EMD Electronics, employing approximately 15,000 people and operating 74 sites and manufacturing facilities.

Key Points: 
  • The businesses of Merck KGaA, Darmstadt, Germany, operate in the U.S and Canada as MilliporeSigma, EMD Serono, and EMD Electronics, employing approximately 15,000 people and operating 74 sites and manufacturing facilities.
  • "In the U.S., the businesses of Merck KGaA, Darmstadt, Germany, aim to lead, not follow.
  • That is why we are immensely proud to have been recognized as a 'Best Place to Work for Disability Inclusion'."
  • In the U.S., the businesses of Merck KGaA, Darmstadt, Germany, offer 30+ programs and projects, including Employee Resource Groups (ERGs), focused on disability inclusion.

EQS-News: APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlschlegel takes over as successor

Retrieved on: 
星期一, 七月 10, 2023
Thompson-Wohlschlegel Round Barn, Supervisory board, Merck Serono, RTÉ Executive Board, Ticker, Merck, Security (finance), Management, Pharmaceutical industry

The Supervisory Board received and accepted Mr. Gast's resignation at its extraordinary meeting today.

Key Points: 
  • The Supervisory Board received and accepted Mr. Gast's resignation at its extraordinary meeting today.
  • At the same time, the Supervisory Board appointed Bruno Wohlschlegel as a member of the Executive Board and as CEO for a period of 2 years with an effective date of 1 September 2023.
  • We wish Mr. Gast all the best.”
    “The change will not have negative implications for the operational business,” Dr. Wiedenfels continued.
  • The first priority for me is to consistently and reliably align the company with the growth strategy according to commercial and operational best practices.”

EMD Serono launches Caregivers Concierge: An online resource hub for caregivers in Alberta

Retrieved on: 
星期四, 六月 15, 2023
Well, Pressure, University, Caregiver, Comp 175: A Benefit for Queer Programs and Services in the Pacific Northwest, Friends, AB, Cancer, Lung cancer, Head, RAPP, Multiple sclerosis, Government, MS, Organization, Ageing, Patient, Love, Palliative care, Research, Merck Serono, Health, Family, Conjugated estrogens, Residential care, Oil

The platform will provide support to the province's one million1 unpaid caregivers with unique offers, resources and services

Key Points: 
  • The platform will provide support to the province's one million1 unpaid caregivers with unique offers, resources and services
    CALGARY, AB, June 15, 2023 /CNW/ - Launching today, Caregivers Concierge™ is an online resource hub developed by EMD Serono that makes finding local resources easier for the one million unpaid caregivers in Alberta.
  • "We believe that supporting caregivers can lead to better patient outcomes, and Caregivers Concierge is one of the many ways EMD Serono is working to build a better network of support for carers."
  • EMD Serono released its first-ever global Carer Well-Being Index in 2021, revealing alarming trends affecting Canadian Caregivers after the pandemic.
  • EMD Serono launched its online portal during its Embracing Carers in Alberta event.

Beaconcure Raises $14 Million Series B to Expand AI-powered Clinical Technology Platform

Retrieved on: 
星期二, 六月 13, 2023
Technology, FDA, Clinical Trials, Software, Biotechnology, General Health, Pharmaceutical, Health, Data Management, Artificial Intelligence, Dark, DevOps, Central Waqf Council, Senior, Life, Face, University, Clinical trial, Patient, Humble Bundle, Biostatistics, Merck Serono, SVP, ChromeOS, Pharmaceutical industry, Fine chemical, Cytel, Pfizer

Beaconcure, Inc., the leading clinical data technology and automation company, today announced the closing of its $14 million Series B financing round.

Key Points: 
  • Beaconcure, Inc., the leading clinical data technology and automation company, today announced the closing of its $14 million Series B financing round.
  • Beaconcure will use proceeds from the round to build on its pioneering position in clinical data validation, to expand its commercial organization, and to bring its next-generation platform to the market.
  • Developed in conjunction with its long-term partner, Pfizer , Beaconcure’s artificial intelligence platform, Verify , streamlines and automates the clinical trial data statistical analysis process.
  • “Beaconcure has a clear mission: to reduce the cost and time to complete every clinical trial.

Optimizing Clinical Trial Supply Chain with End-to-End Condition Monitoring: A Case Study, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
星期一, 六月 12, 2023
Learning, Clinical trial, Merck Serono, Temperature, Patient safety, IRT, Medical device

TORONTO, June 12, 2023 /PRNewswire-PRWeb/ -- The clinical trial supply chain is a complex and sensitive process that requires close monitoring to ensure patient safety. End-to-end condition monitoring is a powerful solution to improve the supply chain's transparency and control.

Key Points: 
  • In this free webinar, learn how end-to-end condition monitoring can improve patient safety and increase process efficiency in the clinical trial supply chain.
  • TORONTO, June 12, 2023 /PRNewswire-PRWeb/ -- The clinical trial supply chain is a complex and sensitive process that requires close monitoring to ensure patient safety.
  • It will also allow for more sustainable processes and a significant reduction of the environmental impact of the clinical trial supply chain.
  • Don't miss this webinar on end-to-end condition monitoring for the clinical trial supply chain and how its adoption can improve patient safety.

Annual General Meeting 2023

Retrieved on: 
星期四, 六月 8, 2023
Exercise, Interim, SIX Swiss Exchange, Shareholder, Senior, Provincial Finance and Accounts Service, Bank statement, Merck Serono, AGM, Statute, Article, USD, PwC, Charles III University of Madrid, Business administration, Acquisition, Management, Executive Committee, Business performance management, Merck, Consolidated, Executive Committee of the Space Research Council, Master of Business Administration, Health, Therapy, CHF, Articles of association, Independent, Annual general meeting, Cryptocurrency, Audit, Holding company, Security (finance), Serono

53 LR of the SIX Swiss Exchange

Key Points: 
  • 53 LR of the SIX Swiss Exchange
    Geneva, Switzerland – June 8, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today published the invitation to its 2023 Annual General Meeting of Shareholders to be held on June 29, 2023, at 10:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland.
  • The Board of Directors proposes the re-election of Perréard de Boccard SA, Rue de la Coulouvrenière 29, 1204 Genève, as Independent Representative of shareholders for a one-year term expiring at the closing of the 2024 Annual General Meeting.
  • The Board of Directors proposes that the shareholders approve a maximum aggregate amount of compensation of CHF 1,250,000 for the members of the Board of Directors for the period from the 2023 Annual General Meeting to the 2024 Annual General Meeting.
  • The full invitation to the AGM 2023 may be found in the general meetings section of the Company's website, [ he r e ].

EMD Serono Highlights Commitment to Improving Cancer Outcomes at ASCO 2023

Retrieved on: 
星期四, 五月 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Carcinoma, Abstract, Abstract (summary), Maintenance, FRCP, INSIGHT, Fighter Interception Development Unit RAF, Health care, Survival, Cancer, Royal Marsden Hospital, Merck Group, Head, NSCLC, Cisplatin, Lung cancer, Neck, Doctor of Philosophy, Continental, The Royal Marsden NHS Foundation Trust, ASCO, FRCR, American Society of Clinical Oncology, UC, Patient, Apoptosis, Annual general meeting, MET, IAP, LA, Merck, Institute of Cancer Research, African Continental Free Trade Area, Merck Serono, Phase, RT, Society, Avelumab, Safety, Pharmaceutical industry

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago.

Key Points: 
  • EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago.
  • This study is assessing xevinapant plus RT in patients with resected, high-risk LA SCCHN who are not eligible for cisplatin.
  • Additional presentations for TEPMETKO include analyses from the INSIGHT 2 study in EGFRm METamp NSCLC for patients treated with TEPMETKO plus osimertinib.
  • In addition to the data being presented at ASCO 2023, EMD Serono will launch a new educational initiative for oncology professionals on the unmet medical need in LA SCCHN, cancer’s resistance to apoptosis, and the role of apoptosis proteins.